Skip to content

Effect of subanesthetic dose esketamine on postoperative pain and sleep quality in patients undergoing lumbar fusion

Effect of subanesthetic dose esketamine on postoperative pain and sleep quality in patients undergoing lumbar fusion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083156
Enrollment
Unknown
Registered
2024-04-17
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lesions of the lumbar spine

Interventions

C group:General anesthesia + intraoperative pumping of normal saline + postoperative sufentanil analgesia group
S group:General anesthesia + intraoperative pumping of esketamine + postoperative esketamine/sufentanil analgesia group

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, male or female, ASA grade I-III; 2. Patients with severe lumbar disc herniation, lumbar spinal stenosis, and lumbar spondylolisthesis instability need to be treated with surgery; 3. Planned general anesthesia; 4. Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with esketamine or esketamine allergy should be contraindicated after comprehensive evaluation; 2. Patients with poorly controlled or untreated hypertension (SBP more than 180mmHg and DBP more than 100mmHg in the resting state); 3. Patients with elevated intracranial pressure and central nervous system injury or disease (except when ventilated appropriately), and patients with a risk of severe elevated intracranial pressure, such as intracranial aneurysm; 4. Patients with ischemic heart disease, congestive heart failure, unstable angina pectoris or myocardial infarction in the past 6 months; 5. Patients with a history of severe mental disorders or using antipsychotic drugs; 6. Patients with high intraocular pressure (such as glaucoma) and penetrating ocular trauma, as well as ocular surgery patients who should not increase intraocular pressure; 7. Patients with a family history of malignant hyperthermia or patients at high risk of malignant hyperthermia (such as strabismus, scoliosis, etc.); 8. Patients with untreated or undertreated hyperthyroidism; 9. No history of drug abuse.

Design outcomes

Primary

MeasureTime frame
Postoperative sleep quality;

Secondary

MeasureTime frame
Visual analogue scale;Ramasy Sedation Score;Cumulative intraoperative opioid consumption;Use of remedial analgesics within 48h after surgery;

Countries

China

Contacts

Public ContactJin Yanwu

The Second Hospital of Shandong University

jinyanwu_aa@163.com+86 176 6008 5535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026